Nektar Therapeutics

NasdaqCM:NKTR Stock Report

Market Cap: US$127.5m

Nektar Therapeutics Future Growth

Future criteria checks 0/6

Nektar Therapeutics's revenue and earnings are forecast to decline at 0.8% and 18.3% per annum respectively. EPS is expected to decline by 11.7% per annum. Return on equity is forecast to be -204.8% in 3 years.

Key information

-18.3%

Earnings growth rate

-11.69%

EPS growth rate

Pharmaceuticals earnings growth14.6%
Revenue growth rate-0.8%
Future return on equity-204.82%
Analyst coverage

Good

Last updated16 May 2025

Recent future growth updates

Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

May 11
Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

Nektar Therapeutics (NASDAQ:NKTR) Analysts Are More Bearish Than They Used To Be

May 15
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are More Bearish Than They Used To Be

Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

May 11
Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Little Excitement Around Nektar Therapeutics' (NASDAQ:NKTR) Revenues As Shares Take 29% Pounding

Apr 04
Little Excitement Around Nektar Therapeutics' (NASDAQ:NKTR) Revenues As Shares Take 29% Pounding
author-image

Phase IIb Data And FDA Fast-Track Will Spur Mixed Prospects

Apr 03 Fast-track designation and strategic partnerships could expedite REZPEG's market entry, enhancing near-term revenue and profit margins.

Lacklustre Performance Is Driving Nektar Therapeutics' (NASDAQ:NKTR) 34% Price Drop

Feb 10
Lacklustre Performance Is Driving Nektar Therapeutics' (NASDAQ:NKTR) 34% Price Drop

Why Investors Shouldn't Be Surprised By Nektar Therapeutics' (NASDAQ:NKTR) 27% Share Price Plunge

Dec 06
Why Investors Shouldn't Be Surprised By Nektar Therapeutics' (NASDAQ:NKTR) 27% Share Price Plunge

Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking

Oct 18
Investor Optimism Abounds Nektar Therapeutics (NASDAQ:NKTR) But Growth Is Lacking

Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

Jun 19
Some Nektar Therapeutics (NASDAQ:NKTR) Shareholders Look For Exit As Shares Take 35% Pounding

There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Feb 15
There's No Escaping Nektar Therapeutics' (NASDAQ:NKTR) Muted Revenues Despite A 44% Share Price Rise

Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Dec 31
Nektar Therapeutics' (NASDAQ:NKTR) Business And Shares Still Trailing The Industry

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Nov 06
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Apr 24
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Invest In Growth?

Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Jan 24
Here's Why Nektar Therapeutics (NASDAQ:NKTR) Must Use Its Cash Wisely

Earnings and Revenue Growth Forecasts

NasdaqCM:NKTR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202735-262-214-2287
12/31/202641-202-175-1758
12/31/202540-180-172-1768
3/31/202587-133-178-177N/A
12/31/202498-119-177-176N/A
9/30/202493-168-178-177N/A
6/30/202493-177-175-175N/A
3/31/202490-176-189-189N/A
12/31/202390-276-193-193N/A
9/30/202388-294-204-203N/A
6/30/202388-307-245-244N/A
3/31/202389-415-269-267N/A
12/31/202292-368-310-304N/A
9/30/202295-454-409-398N/A
6/30/202296-525-430-416N/A
3/31/2022103-491-440-424N/A
12/31/2021102-524-428-413N/A
9/30/2021100-495-371-360N/A
6/30/2021105-474-321-311N/A
3/31/2021126-429-322-312N/A
12/31/2020153-444-321-313N/A
9/30/2020163-439-349-340N/A
6/30/2020163-429-368-356N/A
3/31/2020137-460-347-326N/A
12/31/2019115-441-355-329N/A
9/30/2019121-427-352-321N/A
6/30/2019119-424-352-324N/A
3/31/20191,184657671690N/A
12/31/20181,193681N/A718N/A
9/30/20181,249746N/A755N/A
6/30/20181,374903N/A920N/A
3/31/2018321-129N/A-98N/A
12/31/2017308-97N/A-80N/A
9/30/2017250-105N/A-52N/A
6/30/2017133-209N/A-173N/A
3/31/2017131-198N/A-128N/A
12/31/2016165-154N/A-117N/A
9/30/2016167-165N/A-140N/A
6/30/2016191-130N/A-126N/A
3/31/2016181-134N/A-160N/A
12/31/2015231-81N/A-73N/A
9/30/2015211-73N/A-23N/A
6/30/20152846N/A-55N/A
3/31/201529026N/A-16N/A
12/31/2014201-54N/A-142N/A
9/30/2014212-56N/A-64N/A
6/30/2014140-143N/A-37N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NKTR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NKTR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NKTR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NKTR's revenue is expected to decline over the next 3 years (-0.8% per year).

High Growth Revenue: NKTR's revenue is forecast to decline over the next 3 years (-0.8% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: NKTR is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 08:30
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nektar Therapeutics is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Aydin HuseynovBenchmark Company
George FarmerBMO Capital Markets Equity Research